AngioDynamics Appoints Stephen Trowbridge Executive Vice President and Chief Financial Officer
February 06 2020 - 8:00AM
Business Wire
AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of
innovative, minimally invasive medical devices for vascular access,
peripheral vascular disease, and oncology, today announced that it
has appointed Stephen Trowbridge to the role of Executive Vice
President and Chief Financial Officer, effective February 5,
2020.
Mr. Trowbridge has served as the Company’s Interim Chief
Financial Officer since October 22, 2019, in addition to his
responsibilities as Senior Vice President and General Counsel.
AngioDynamics will initiate a search for the role of General
Counsel; to facilitate a smooth transition, Mr. Trowbridge will
retain his duties as General Counsel until a replacement is
named.
“We are thrilled to have Steve assume the CFO role full-time and
lead our outstanding finance organization,” said Jim Clemmer,
AngioDynamics President and Chief Executive Officer. “Steve and I
have worked together for several years, and I have experienced
first-hand his leadership, talent, and passion for our business and
patients. I’m confident that the unique insights Steve has
developed during his 11 years at AngioDynamics will be instrumental
as we continue our transformation into a more technology-focused
medical device company.”
“I am excited to assume the CFO role on a permanent basis,” said
Stephen Trowbridge, AngioDynamics Executive Vice President and
Chief Financial Officer. “I look forward to continuing to work
closely with Jim and the rest of the team as we enter larger,
faster-growing markets and bring innovative new products to
healthcare professionals and patients around the globe.”
Mr. Trowbridge joined AngioDynamics as Corporate Counsel in
2008, was promoted to Vice President and General Counsel in 2010,
and subsequently promoted to Senior Vice President, General Counsel
in 2013. Prior to AngioDynamics, Mr. Trowbridge served as Corporate
Counsel at Philips Healthcare and Intermagnetics General
Corporation. Mr. Trowbridge began his career with Cadwalader,
Wickersham & Taft, LLP in the firm’s Mergers and Acquisitions
and Securities Group.
Mr. Trowbridge received a Bachelor of Science in Science and
Technology Studies from Rensselaer Polytechnic Institute, a Juris
Doctor from the University of Pennsylvania Law School, and a Master
of Business Administration from Duke University’s Fuqua School of
Business.
About AngioDynamics, Inc.
AngioDynamics, Inc. is a leading provider of innovative,
minimally invasive medical devices used by professional healthcare
providers for vascular access, peripheral vascular disease, and
oncology. AngioDynamics’ diverse product lines include
market-leading ablation systems, vascular access products,
angiographic products and accessories, drainage products,
thrombolytic products and venous products. For more information,
visit www.angiodynamics.com.
Safe Harbor
This release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
All statements regarding AngioDynamics' expected future financial
position, results of operations, cash flows, business strategy,
budgets, projected costs, capital expenditures, products,
competitive positions, growth opportunities, plans and objectives
of management for future operations, as well as statements that
include the words such as "expects," "reaffirms," "intends,"
"anticipates," "plans," "believes," "seeks," "estimates,"
"optimistic," or variations of such words and similar expressions,
are forward-looking statements. These forward-looking statements
are not guarantees of future performance and are subject to risks
and uncertainties. Investors are cautioned that actual events or
results may differ from AngioDynamics' expectations. Factors that
may affect the actual results achieved by AngioDynamics include,
without limitation, the ability of AngioDynamics to develop its
existing and new products, technological advances and patents
attained by competitors, infringement of AngioDynamics' technology
or assertions that AngioDynamics' technology infringes the
technology of fourth parties, the ability of AngioDynamics to
effectively compete against competitors that have substantially
greater resources, future actions by the FDA or other regulatory
agencies, domestic and foreign health care reforms and government
regulations, results of pending or future clinical trials, overall
economic conditions, the results of on-going litigation, challenges
with respect to fourth-party distributors or joint venture partners
or collaborators, the results of sales efforts, the effects of
product recalls and product liability claims, changes in key
personnel, the ability of AngioDynamics to execute on strategic
initiatives, the effects of economic, credit and capital market
conditions, general market conditions, market acceptance, foreign
currency exchange rate fluctuations, the effects on pricing from
group purchasing organizations and competition, the ability of
AngioDynamics to integrate acquired businesses, as well as the risk
factors listed from time to time in AngioDynamics' SEC filings,
including but not limited to its Annual Report on Form 10-K for the
year ended May 31, 2019. AngioDynamics does not assume any
obligation to publicly update or revise any forward-looking
statements for any reason.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200206005232/en/
Investor Relations: AngioDynamics, Inc Stephen Trowbridge
518-795-1408 strowbridge@angiodynamics.com
Media: AngioDynamics, Inc. Saleem Cheeks 518-795-1174
scheeks@angiodynamics.com
AngioDynamics (NASDAQ:ANGO)
Historical Stock Chart
From Aug 2024 to Sep 2024
AngioDynamics (NASDAQ:ANGO)
Historical Stock Chart
From Sep 2023 to Sep 2024